Analyst Reco. Bristol-Myers Squibb Company Xetra

Equities

BRM

US1101221083

Market Closed - Xetra Other stock markets 16:35:32 26/06/2024 BST			5-day change	1st Jan Change
39.85 ^EUR	+0.99%		+4.17%	-14.12%

06-26	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT
06-26	Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	05-01	MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	04-30
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	04-29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	04-29	MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	04-26	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	04-26	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	04-26	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	04-26	MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40	04-26	MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	04-26	MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55	04-26	MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating	04-25	MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating	04-25	MT
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating	04-22	MT
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	04-18	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	04-15	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	04-15	MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58	04-12	MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating	04-09	MT
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85	03-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 06:06 pm